Brind.

Moderna's stock gains are being driven by FDA approval and the broader growth of AI businesses, as a Nasdaq constituent.

1 report, 1 independent Updated Oct 17

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Moderna Nasdaq FDA

Keep exploring

The entities involved

Moderna
American biotechnology company
- Scottish Mortgage Investment Trust, managed by Baillie Gifford, highlighted its key holdings in SpaceX and Moderna.Fri 17:13
- Moderna is being led through strategic pivots by CEO Stéphane Bancel.Fri 15:45
Nasdaq
American fully electronic stock exchange
- An AI stock sell-off impacted Nasdaq on November 5, 2026, following the election results.01:20
- BioVie Inc. shares are traded on Nasdaq, and MarketBeat reported its average stock rating.00:59
FDA
- The FDA approved Miplyffa for the treatment of Niemann-Pick disease.00:55
- iRhythm Technologies launched its Zio ECG system in Japan following FDA clearance, amid reports that Trump-era tariffs benefit AI stocks.Fri 23:50

Related events

MarketBeat listed Regeneron Pharmaceuticals, AbbVie, and Moderna as stocks to watch on October 31, 2026.Sat 16:45
Moderna and Merck developed the intismeran autogene therapy.Oct 29

Coverage

Newest first; wire copies grouped

Oct 17fool.com